By Michael Tetreault and Dr. Joshua Hare | Concierge Medicine Today’s “DocPreneur Leadership Podcast”
Today on the DocPreneur Leadership Podcast at Concierge Medicine Today we sit down with Dr. Joshua Hare Chief Science Officer at Longeveron, a life sciences company developing biological solutions for aging and aging-associated diseases through the testing of allogeneic human Mesenchymal Stem Cells (MSCs) that are derived from the bone marrow of young, healthy donors. Dr. Hare is also the Founding Director of the University of Miami Interdisciplinary Stem Cell Institute (ISCI). Through his work with ISCI, Hare has made significant advances in the field of stem cell regenerative medicine, including the creation of relevant intellectual property.
Dr. Joshua Hare co-founded Longeveron in 2014 utilizing intellectual property and technology exclusively licensed from the University of Miami, where he is also the Founding Director of the university’s Interdisciplinary Stem Cell Institute (ISCI). Through his work with ISCI, Hare has made significant advances in the field of stem cell regenerative medicine, including the creation of relevant intellectual property.
A graduate of the University of Pennsylvania (1984) and the Johns Hopkins University School of Medicine (1988), Hare completed fellowships at Johns Hopkins and Brigham and Women’s Hospital in Boston, Ma. He served as a research fellow at Harvard University and is Board Certified in cardiovascular medicine. During his career, Hare has championed the field of allogeneic cell therapy, and he has conducted five clinical trials using allogenic cell therapy. Hare’s publications in the area of cell-based therapy are widely cited, and he holds six Investigational New Drug (IND) authorizations from the FDA for cell therapy drugs and treatments in patients with heart disease. Hare co-founded Longeveron as a means to bring his academic findings to patients with unmet medical needs.
Hare’s extensive list of accolades and professional experience includes:
- Director, Interdisciplinary Stem Cell Institute (ISCI)
- Louis Lemberg Professor of Medicine (cardiology), Leonard M. Miller School of Medicine, University of Miami
- Professor of Biomedical Engineering
- Professor of Molecular and Cellular Pharmacology
- Professor of Cell Biology and Anatomy
- Nominated in 2011 to the Association of American Physicians
Stem cell therapy is emerging as a promising new treatment option for chronic diseases and injuries affecting various organ systems. One of the most exciting ideas emerging from the field of regenerative medicine is the theory that stem cells can treat aging-related disability and frailty, reducing inflammation and improving functional capacity and quality of life for human beings. Stem cells have the potential to increase longevity and could ameliorate diseases and disorders associated with aging.
Currently there are no FDA-approved allogeneic mesenchymal stem cell treatments in the United States. Longeveron’s LMSCs are currently undergoing rigorous testing for safety and efficacy in Phase I and II clinical trials. They hope to be the first to offer stem cells as a safe, effective, FDA-approved treatment for some of the world’s most difficult chronic and life-threatening conditions such as Aging Frailty, Alzheimer’s disease and the Metabolic Syndrome.